Gary Heimberg’s practice focuses on public policy and government affairs matters for pharmaceutical, medical device and consumer health care clients. He has substantive knowledge of the current legislative and policy issues facing the Life Sciences industry, including in the areas of intellectual property, pricing, oversight & investigations, OTC medicines, vaccines, biodefense, and FDA reform. Mr. Heimberg has also facilitated the implementation of internal corporate policies and procedures to adhere to federal compliance requirements.
Mr. Heimberg’s pharmaceutical industry experience spans all spheres, including in-house, trade association, government and private practice positions.
Articles in the National Law Review database by Gary A. Heimberg